Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Variants & evidence
156 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA H1047R4 | ||||||||
| Pictilisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID2096This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Se… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID6203This preclinical study tested the effect of trastuzumab (an anti-HER2 drug) on HER2-positive breast cancer cell lines (BT474 and SKBR3) retrovirally transduced with H1047R. The study found that the H1… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8548As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resi… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2103As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expre… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA H1047L + PIK3CA H1047R1 | ||||||||
| (prognostic) | Breast Tubular Carcinoma | Prognostic | B | Supports Poor Outcome | 1 | accepted | EID3047In a retrospective analysis of 32 Western Chinese female patients with invasive ductal breast cancer, PIK3CA H1047L (n=1) or H1047R (n=8) was associated with worse survival and increased incidence of … (full text at CIViC) PMID 28269754 · Cheng et al., 2017 · Open in CIViC | civic |
| PIK3CA I391M2 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8663As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was ass… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2867As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associate… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA K111N7 | ||||||||
| Dactolisib + Lapatinib + TrastuzumabSubstitutes | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8183The BT-474 HER2 positive human breast cancer cell line, which is heterozygous for the PIK3CA K111N mutation, demonstrated strongly reduced colony formation when treated with lapatinib, trastuzumab or … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| PI-103 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID8011As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| PIK3CA K111N + PTEN UnderexpressionPIK3CAPTEN7 | ||||||||
| Dactolisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8276In a preclinical study, efficacy of dactolisib monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN exp… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8283In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expr… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | |
| PIK3CA Mutation9 | ||||||||
| Bazedoxifene + Palbociclib RegimenCombination | Breast Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 4 | submitted | EID12619In a phase Ib/II trial of bazedoxifene 40 mg daily plus palbociclib 125 mg (NCT02448771; HR positive, HER2 negative breast carcinoma; n = 36), the regimen produced a 24 week clinical benefit rate of 3… (full text at CIViC) PMID 36215125 · Tsuji et al., 2022 · Open in CIViC | civic |
| Capecitabine + LapatinibCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID8705In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PIK3CA Overexpression4 | ||||||||
| Dactolisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8269In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) monotherapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PIK3CA amplification. Auth… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID8268In a preclinical study, efficacy of lapatinib monotherapy was evaluated in vitro against HER2 amplified breast cancer cell lines (BT474 and SKBR3) with retrovirally induced PIK3CA expression. Authors … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib + TrastuzumabCombination | ||||||||
| PTEN Expression1 | ||||||||
| Everolimus + FulvestrantCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID1624Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classica… (full text at CIViC) PMID 27445490 · Sun et al., 2016 · Open in CIViC | civic |
| PTEN Loss11 | ||||||||
| Dactolisib + Lapatinib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8280In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induc… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Everolimus | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1297Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC) PMID 27091708 · André et al., 2016 · Open in CIViC | civic |
| PTPN12 Loss-of-function1 | ||||||||
| Crizotinib + SunitinibCombination | Triple-Negative Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID6931Cancer-associated mutation of PTPN12 or reduced PTPN12 protein leads to aberrant activity of several tyrosine kinase receptors (MET, PDGFRβ, EGFR, and others). Restoring PTPN12 protein levels restrain… (full text at CIViC) PMID 29578538 · Nair et al., 2018 · Open in CIViC | civic |
| RB1 Loss-of-function3 | ||||||||
| Checkpoint Kinase Inhibitor AZD7762 | Triple-Negative Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12330A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC) PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC | civic |
| Gemcitabine | Triple-Negative Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12329A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC) PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC | civic |
| Volasertib | ||||||||
Data updated 10 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| HER2-Positive Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 1 |
| accepted |
EID8020As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC |
| civic |
| Pictilisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID2085This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Se… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 3 | rejected | EID8550As part of a pre-clinical experiment, the efficacy of trastuzumab was compared to that of ado-trastuzumab emtansine (T-DM1) against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8662As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associat… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 3 | accepted | EID2866As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated … (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| civic |
| Lapatinib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 4 | accepted | EID8275In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + LapatinibCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8278In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and lapatinib combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (h… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Lapatinib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID8277In a preclinical study, efficacy of lapatinib and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induced PTEN expression loss. A… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8274In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN ex… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| Dactolisib + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Does Not Support Resistance | 2 | accepted | EID8279In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified human breast cancer cell line … (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| HER2-Positive Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 2 |
| accepted |
EID1504HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZ… (full text at CIViC) PMID 22294718 · Davies et al., 2012 · Open in CIViC |
| civic |
| Everolimus | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1296Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC) PMID 27091708 · André et al., 2016 · Open in CIViC | civic |
| Nab-paclitaxel | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 2 | submitted | EID13086Targeted NGS of 17 genes was utilized to assess alterations in pre-treatment tumour biopsy samples of HER2+ breast cancers from the prospective GeparSepto (G7) trial of anti-HER2 therapy (trastuzumab/… (full text at CIViC) PMID 41974716 · Van Mackelenbergh et al., 2026 · Open in CIViC | civic |
| Pertuzumab/Trastuzumab Regimen | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 3 | submitted | EID13085Targeted NGS of 17 genes was utilized to assess alterations in pre-treatment tumour biopsy samples of HER2+ breast cancers from the prospective GeparSepto (G7) trial of combination trastuzumab plus pe… (full text at CIViC) PMID 41974716 · Van Mackelenbergh et al., 2026 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID2098In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a … (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 2 | accepted | EID1384The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proli… (full text at CIViC) PMID 17936563 · Berns et al., 2007 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Does Not Support Resistance | 3 | accepted | EID8536In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| HER2-Positive Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 2 |
| accepted |
EID8270In a preclinical study, efficacy of lapatinib and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell lines (BT474 and SKBR3) with retrovirally induced PIK… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC |
| civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID8267HER2-positive breast cancer cell lines (BT-474 and SKBR3) were retrovirally transduced with wildtype PIK3CA and treated with trastuzumab. PIK3CA overexpression diminished the growth inhibitory effects… (full text at CIViC) PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC | civic |
| HER2-Positive Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 1 |
| accepted |
EID8012As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC |
| civic |
| PI3Ka/Di | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 1 | accepted | EID8022As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Pictilisib | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID2045This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 3 | accepted | EID1385A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Does Not Support Resistance | 3 | accepted | EID1386While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second o… (full text at CIViC) PMID 20813970 · Esteva et al., 2010 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Supports Resistance | 2 | accepted | EID2035In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured … (full text at CIViC) PMID 21594665 · Razis et al., 2011 · Open in CIViC | civic |
| 〃 | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID1383A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in… (full text at CIViC) PMID 17936563 · Berns et al., 2007 · Open in CIViC | civic |
| Trastuzumab Emtansine | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Does Not Support Resistance | 3 | accepted | EID8706In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ad… (full text at CIViC) PMID 26920887 · Baselga et al., 2016 · Open in CIViC | civic |
| PI3K/BET Inhibitor LY294002 + TrastuzumabCombination | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1455Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition,… (full text at CIViC) PMID 15324695 · Nagata et al., 2004 · Open in CIViC | civic |
| Triple-Negative Breast CarcinomaALIAS |
| Predictive |
| D |
| Supports Sensitivity Response |
| 3 |
| submitted |
EID12331A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC) PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC |
| civic |